Last week @bridges2develop.bsky.social's Julie Jacobson was proud to participate in @mundosano.bsky.social 's 1st annual Global Health conference in Madrid! She spoke to challenges in NTD elimination and solutions like
@stop2030.org novel fixed-dose IVM and ALB coformulation for STH. #beatNTDs
@stop2030.org novel fixed-dose IVM and ALB coformulation for STH. #beatNTDs
June 3, 2025 at 10:35 PM
Last week @bridges2develop.bsky.social's Julie Jacobson was proud to participate in @mundosano.bsky.social 's 1st annual Global Health conference in Madrid! She spoke to challenges in NTD elimination and solutions like
@stop2030.org novel fixed-dose IVM and ALB coformulation for STH. #beatNTDs
@stop2030.org novel fixed-dose IVM and ALB coformulation for STH. #beatNTDs
Just stumbled upon this paper from 2021 and what a cool idea:
journals.aai.org/jimmunol/art...
Formulating a vaccine with tattoo ink to let you track exactly where the vaccine goes in animals
journals.aai.org/jimmunol/art...
Formulating a vaccine with tattoo ink to let you track exactly where the vaccine goes in animals
Coformulation with Tattoo Ink for Immunological Assessment of Vaccine Immunogenicity in the Draining Lymph Node
Key Points. Lymphatic drainage of Ags from i.m. vaccinations can be stochastic.Coformulating vaccines with tattoo ink improved draining lymph node identifi
journals.aai.org
August 29, 2024 at 11:07 PM
Just stumbled upon this paper from 2021 and what a cool idea:
journals.aai.org/jimmunol/art...
Formulating a vaccine with tattoo ink to let you track exactly where the vaccine goes in animals
journals.aai.org/jimmunol/art...
Formulating a vaccine with tattoo ink to let you track exactly where the vaccine goes in animals
4/8 The KEYVIBE program—Merck's coformulation of pembrolizumab and vibostolimab—has now been terminated in two major Phase 3 arms: one in metastatic non-small cell lung cancer (MK-7684A-007) and one in adjuvant melanoma (MK-7684A-010), both discontinued in mid-September.
September 18, 2026 at 1:25 PM
4/8 The KEYVIBE program—Merck's coformulation of pembrolizumab and vibostolimab—has now been terminated in two major Phase 3 arms: one in metastatic non-small cell lung cancer (MK-7684A-007) and one in adjuvant melanoma (MK-7684A-010), both discontinued in mid-September.
#liver2013 debrief mentions coformulation of sofosbuvir/ledipasvir as single pill. Another coformulation, asunaprevir/daclatasvir/BMS-791325
December 3, 2024 at 3:03 PM
#liver2013 debrief mentions coformulation of sofosbuvir/ledipasvir as single pill. Another coformulation, asunaprevir/daclatasvir/BMS-791325
Our vision for a better tool for parasite control is becoming a reality. Ghana FDA has approved our fixed-dose coformulation of ivermectin and albendazole.
January 28, 2026 at 8:18 AM
Our vision for a better tool for parasite control is becoming a reality. Ghana FDA has approved our fixed-dose coformulation of ivermectin and albendazole.
From the start, the STOP projects have aimed to advance an innovative tool to fight STH infections. Now, with our fixed-dose coformulation in Phase IV trials, we’re closer than ever to delivering endemic countries with a new medicine for their NTD control goals!
🌍 Learn more 👉 stop2030.org/project/
🌍 Learn more 👉 stop2030.org/project/
Project - STOP2030
Our approach at STOP2030 is to combine two existing drugs into a single tablet that allows a more efficient and affordable treatment of helminthic infections. These two compounds are albendazole and…
stop2030.org
January 12, 2026 at 9:00 AM
From the start, the STOP projects have aimed to advance an innovative tool to fight STH infections. Now, with our fixed-dose coformulation in Phase IV trials, we’re closer than ever to delivering endemic countries with a new medicine for their NTD control goals!
🌍 Learn more 👉 stop2030.org/project/
🌍 Learn more 👉 stop2030.org/project/
The REALISE study, our clinical trial to evaluate the safety in large populations of our fixed-dose coformulation of ivermectin and albendazole (FDC), has reached an important milestone.
October 1, 2025 at 2:43 PM
The REALISE study, our clinical trial to evaluate the safety in large populations of our fixed-dose coformulation of ivermectin and albendazole (FDC), has reached an important milestone.
Pembrolizumab plus lenvatinib/belzutifan, as well as a coformulation of pembrolizumab/quavonlimab in combination with lenvatinib, failed to yield PFS or OS benefits in frontline advanced clear cell RCC #kcsm #oncology
An update from the phase 3 LITESPARK-012 trial: www.onclive.com/view/pembrol...
An update from the phase 3 LITESPARK-012 trial: www.onclive.com/view/pembrol...
Pembrolizumab-Based Combinations Miss the Mark in Frontline ccRCC | OncLive
Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.
www.onclive.com
April 21, 2026 at 4:23 PM
Pembrolizumab plus lenvatinib/belzutifan, as well as a coformulation of pembrolizumab/quavonlimab in combination with lenvatinib, failed to yield PFS or OS benefits in frontline advanced clear cell RCC #kcsm #oncology
An update from the phase 3 LITESPARK-012 trial: www.onclive.com/view/pembrol...
An update from the phase 3 LITESPARK-012 trial: www.onclive.com/view/pembrol...
The Editorial of our Formulation Special Collection is now online. Many thanks to the guest editors Dr. Qingyan Hu of @regeneron.com and Dr. Frank Li of @elilillyandcompany.bsky.social.
doi.org/10.1093/abt/...
#Formulation #Antibody #mAb #ADC #Lyo #HighConcentration #Coformulation
doi.org/10.1093/abt/...
#Formulation #Antibody #mAb #ADC #Lyo #HighConcentration #Coformulation
Opportunities in formulation development of antibody-based therapeutics
Abstract. Drug product formulation transforms active pharmaceutical ingredients into drug products, ensuring stability, manufacturability, efficacy, and pa
doi.org
September 15, 2025 at 12:23 AM
The Editorial of our Formulation Special Collection is now online. Many thanks to the guest editors Dr. Qingyan Hu of @regeneron.com and Dr. Frank Li of @elilillyandcompany.bsky.social.
doi.org/10.1093/abt/...
#Formulation #Antibody #mAb #ADC #Lyo #HighConcentration #Coformulation
doi.org/10.1093/abt/...
#Formulation #Antibody #mAb #ADC #Lyo #HighConcentration #Coformulation